Media coverage about SciClone Pharmaceuticals (NASDAQ:SCLN) has trended positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SciClone Pharmaceuticals earned a daily sentiment score of 0.30 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 43 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

SciClone Pharmaceuticals (SCLN) traded down 0.228% during mid-day trading on Monday, hitting $10.925. 145,369 shares of the stock traded hands. The stock has a 50-day moving average of $10.18 and a 200 day moving average of $10.02. SciClone Pharmaceuticals has a 1-year low of $8.55 and a 1-year high of $13.46. The firm has a market cap of $565.17 million, a price-to-earnings ratio of 15.366 and a beta of 1.70.

Separately, Maxim Group restated a “hold” rating on shares of SciClone Pharmaceuticals in a research note on Thursday, June 8th.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at

In other news, CEO Friedhelm Blobel sold 40,000 shares of the business’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $9.56, for a total transaction of $382,400.00. Following the completion of the transaction, the chief executive officer now owns 104,204 shares of the company’s stock, valued at $996,190.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Wilson Wai-Shun Cheung sold 40,500 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $10.75, for a total transaction of $435,375.00. Following the transaction, the chief financial officer now directly owns 14,372 shares of the company’s stock, valued at approximately $154,499. The disclosure for this sale can be found here. In the last three months, insiders have sold 298,126 shares of company stock valued at $3,088,468. Corporate insiders own 5.16% of the company’s stock.

About SciClone Pharmaceuticals

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Insider Buying and Selling by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.